DSEK: the pros and cons

Article

DSEK: the pros and cons

Descemet's stripping with endothelial keratoplasty provides significant advantages over penetrating keratoplasty (PK), according to a study published in the March 2006 issue of the Journal of Cataract & Refractive Surgery.

The Price Vision Group, under the direction of Francis Price Jr., MD and Marianne Price, PhD, analysed the outcomes of 200 consecutive DSEK procedures, performed by the same surgeon, in order to establish early challenges associated with the method, as well as techniques required to promote donor tissue adherence.

The technique involved stripping Descemet's membrane and endothelium from the recipient's central cornea and transplanting an 8.0 to 9.0 mm disc of donor endothelium and posterior stroma through a 5.0 mm incision, with sutures used simply to close the incision. Follow-up was seven to 20 months for 124 eyes and two to six months for 76 eyes.

At the study's conclusion, the investigators admitted that the most frequent challenge was inadequate donor attachments. Any incidences of donor detachment were remedied by injecting an air bubble to press the donor against the recipient cornea. While there were seven primary graft failures, only one occurred in the second lot of 100 cases, which primarily used microkeratome-dissected donor tissue. Other, very rare, complications included papillary block glaucoma, cataract development and aqueous misdirection. However, DSEK was performed successfully following LASIK.

The authors concluded that DSEK did indeed offer certain advantages over PK, including more rapid healing, predictable refractive outcomes and enhanced corneal strength and integrity. Though the study group admitted donor adherence was slightly trickier, the procedure itself was technically easier and hence should be less traumatic to anterior chamber structures.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.